A Phase II Study of the Anti-GITR Agonist INCAGN01876 and the PD-1 Inhibitor INCMGA00012 in Combination with Stereotactic Radiosurgery in Recurrent Glioblastoma

Recruiting
99 years or below
All
Phase 2
32 participants needed
1 Location

Brief description of study

The following protocol is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and SRS for recurrent GBM. We hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses. The purpose of this protocol is to determine the efficacy of the combination of INCMGA00012, INCAGN01876, and SRS in recurrent GBM, as measured by the overall objective response rate (ORR). INCAGN01876 (anti-GITR) 300mg will be administered IV every 2 weeks until disease progression, unacceptable toxicity, or 2 years, whichever occurs first. INCMGA00012 (anti-PD1) 500mg will be administered IV every 4 weeks until disease progression, unacceptable toxicity, or 2 years, whichever occurs first.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 12 Dec 2019. Study ID: 834197

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.